Monday, September 15, 2014 8:19:58 AM
Milestone Scientific Receives CE Mark Approval for Intra-Articular Instrument
LIVINGSTON, NJ--(Marketwired - September 15, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its subsidiary, Milestone Medical, has received CE Mark regulatory approval to market and sell its intra-articular instrument in Europe.
Leonard Osser, Chief Executive Officer of Milestone Scientific stated, "Receipt of regulatory approval in Europe for this instrument is validation of our technology and allows our subsidiary to move forward with its plans to commercialize the technology in Europe. Our subsidiary is now in the process of evaluating potential strategic partners to distribute its intra-articular instrument in Europe. We believe we are well positioned to enter this multi-billion dollar market since conventional injections are painful, a problem eliminated with our instrument, and not always efficacious, as doctors often fail to locate the intra-articular space or use inappropriate volumes of hyaluronic acid."
Milestone's injection technology is based on a patented Dynamic Pressure Sensing® system (DPS®), intended to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection. The system utilizes computer controlled technology to provide real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient. It has the added advantage in other applications of controlling the pain that patients typically associate with injections.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
Source: Marketwired (September 15, 2014 - 7:30 AM EDT)
News by QuoteMedia
Recent MLSS News
- Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2024 • GlobeNewswire Inc. • 05/16/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:01:31 PM
- Milestone Scientific Schedules First Quarter 2024 Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 05/13/2024 12:30:00 PM
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023 • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 03/28/2024 03:45:00 PM
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Omaha Pain Physicians • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® with Meridian Endo & Perio • GlobeNewswire Inc. • 02/28/2024 01:30:00 PM
- Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® to Maine Dental Group, a Premier Group Practice with 21 Locations Across the Northeast • GlobeNewswire Inc. • 02/20/2024 01:30:00 PM
- Milestone Scientific CEO Provides Letter to Shareholders; Provides Positive Reimbursement Update • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:34:33 PM
- Milestone Scientific Inc. Announces Closing of $3.0 Million Public Offering of Common Stock • GlobeNewswire Inc. • 12/13/2023 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 05:01:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 10:21:29 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/12/2023 10:10:53 PM
- Milestone Scientific Inc. Announces Pricing of $3.0 Million Public Offering of Common Stock • GlobeNewswire Inc. • 12/11/2023 01:33:45 AM
- Milestone Scientific Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 12/08/2023 09:03:25 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/08/2023 09:00:28 PM
- Milestone Scientific Commences Sales of CompuFlo® Disposables for Use in Neurostimulation Spinal Cord Implantation Procedures • GlobeNewswire Inc. • 12/08/2023 01:30:00 PM
- Milestone Announces Agreement with Bioline Supply to Distribute the CompuFlo® Epidural System and Related Disposables Across Spain • GlobeNewswire Inc. • 11/28/2023 01:30:00 PM
- Milestone Scientific Achieves Revenue of $2.1 Million and Provides Business Update for the Third Quarter of 2023 • GlobeNewswire Inc. • 11/15/2023 12:00:00 PM
- Milestone Scientific Schedules Third Quarter 2023 Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 11/10/2023 01:30:00 PM
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Island Ambulatory Surgery Center in Brooklyn, New York • GlobeNewswire Inc. • 11/09/2023 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/31/2023 04:15:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 09:40:04 PM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM